The diagnosis of diseases leading to brain injury, such as stroke, Alzheimer disease, and Parkinson disease, can often be problematic. In this study, we pursued the discovery of biomarkers that might be specific and sensitive to brain injury. Methods: We performed gene array analyses on a mouse model to look for biomarkers that are both preferentially and abundantly produced in the brain. Via bioinformatics databases, we identified the human homologs of genes that appeared abundant in brain but not in other tissues. We then confirmed protein production of the genes via Western blot of various tissue homogenates and assayed for one of the markers, visinin-like protein 1 (VLP-1), in plasma from patients after ischemic stroke. Results: Twenty-nine genes that were preferentially and abundantly expressed in the mouse brain were identified; of these 29 genes, 26 had human homologs. We focused on 17 of these genes and their protein products on the basis of their molecular characteristics, novelty, and/or availability of antibodies. Western blot showed strong signals in brain homogenates for 13 of these proteins. Tissue specificity was tested by Western blot on a human tissue array, and a sensitive and quantitative sandwich immunoassay was developed for the most abundant gene product observed in our search, VLP-1. VLP-1 was detected in plasma of patients after stroke and in cerebrospinal fluid of a rat model of stroke. Conclusions: The use of relative mRNA production appears to be a valid method of identifying possible biomarkers of tissue injury. The tissue specificity suggested by gene expression was confirmed by Western
Stroke is the third most common cause of death worldwide, after ischemic heart disease and malignancies, and ϳ700 000 patients in the US have a new or recurrent stroke each year (1 ) . The clinical diagnosis of stroke by specialists is reasonably accurate. On clinical grounds but in general practice, up to 20% of the patients suspected of stroke have a different diagnosis (2 ) .
The evaluation of patients with suspected stroke, an acute brain injury, would be greatly aided by the availability of a readily measured biomarker such as is available for acute coronary syndrome and myocardial infarction, e.g., troponin I or troponin T (3 ). Such a brain biomarker for brain injury might also be useful in chronic neurodegenerative diseases.
There have been several studies of possible biomarkers of acute brain damage such as stroke, with S-100B, neuron-specific enolase (NSE), 1 glial fibrillary associated protein (GFAP), and myelin basic protein (MBP) generating the most interest.
S-100B (4 ) is found at high concentrations in glial and Schwann cells. Numerous reports (4 ) show that S-100B is increased in blood and cerebrospinal fluid (CSF) after traumatic brain damage, stroke, and a variety of neurodegenerative diseases. The increase of S-100B in serum after acute ischemic stroke peaks at 2-3 days, and it can be observed at ϳ12 h (5 ). S-100B does not appear to be specific for brain injury; high amounts of S-100B are released in response to trauma of muscle, fat, and bone, and values in trauma without head injury are also increased (6) (7) (8) .
NSE (9 ) has been found to increase after brain injury, such as stroke (10, 11 ) , but it is also increased in cancers of neuroendocrine origin, such as small-cell lung cancer, neurobastoma, carcinoid tumors, and melanoma (12 ) . In addition, hemolysis has been reported to cause positive interference in at least one of the commercially available procedures for its measurement (13 ) .
GFAP is a monomeric intermediate filament protein thought to be produced almost exclusively in astrocytes. It has been reported to be increased after stroke, with peak values around 3 days (14 ) . Recently, promising results for fatty acid binding proteins after ischemic stroke have been reported as well (15 ) .
Other efforts to identify stroke have included the monitoring of hemostatic function. D-dimer appears to be more sensitive than other hemostatic markers, such as fibrinopeptide A and B-thromboglobulin, particularly for cardioembotic stroke (16, 17 ) .
Inflammatory markers have been studied as well, including various cytokines (18 ) and matrix metalloproteinases (MMPs), particularly MMP-9 (gelatinase B) (18) (19) (20) ; MMP-9 is associated with hemorrhagic transformation (20 ) .
Recently, several studies combining various biomarkers have been reported. McGirth et al. (21 ) reported that a combination of serum von Willebrand factor, MMP-9, and vascular endothelial growth factor could predict the onset of cerebral vasospasm and subarachoid hemorrhage. Another study reported that S-100B, B-type neurotrophic growth factor, von Willebrand factor, MMP-9, and monocyte chemotactic protein-1 could be effectively used. The authors stated that if any 3 of the 5 biomarkers exceeded their reference range, then the sensitivity was 92% and specificity was 93% for ischemic stroke for samples taken within 6 h from symptom onset (22 ) . Another study screened 26 biomarkers and found that 4 were highly correlated with stroke: S100-B, MMP-9, vascular cell adhesion molecule, and von Willebrand factor (23 ) .
Proteomic approaches have been used with only moderate success to identify potential brain biomarkers (24) (25) (26) (27) . A consortium has been formed, The Human Brain Proteome Project, to facilitate the identification of brain proteins that may be involved in disease (http://www. hupo.org).
Despite a large amount of effort, there have been few successful systematic approaches to the discovery of new brain biomarkers for disease such as stroke.
Materials and Methods gene array analysis and bioinformatics
We systematically approached the identification of brain biomarkers by seeking genes expressed in brain, at least 10-fold higher than in other tissues. We elected to use mice for our experiments so that we could obtain nondegraded mRNA. With the advent of mouse gene expression arrays and the complete DNA sequence of mice and human available, we thought this approach well worth exploring.
Brain, liver, spleen, kidney, skeletal muscle, lung, pancreas, heart, and small intestine from 3 (2 male and 1 female) C57BL/6 mice (Jackson Laboratory), ages 4 -6 weeks, were obtained by careful dissection. The organ samples were snap frozen in liquid nitrogen and processed as described (28 ) to isolate RNA. The quality of the RNA was confirmed by (a) spectrophotometry of RNA with an A 260 /A 280 ratio Ͼ1.9, and (b) a 28S/18S ratio of extracted RNA Ͼ1.4, as observed by RNA LabChip (Agilent 2100 Bioanalyzer RNA 6000 LabChip reagent set).
Ten micrograms of the total RNA was converted to double-stranded cDNA with an oligo(dT) primer containing the T7 promoter and used to prepare biotinylated cRNA with the Bioarray HighYield reagent set (Enzo) according to the manufacturer's directions. The biotinylated cRNA probes were fragmented and applied as described (29, 30 ) to Mouse MU74A (Version 1) Genechip® arrays (Affymetrix). The overall fluorescence intensity across each chip was scaled to 1500 with Affymetrix analysis software Microarray Suite. The data were transferred to a Microsoft Excel worksheet. One selection criterion was gene expression, with mean difference values Ͼ10 000 in the brain (i.e., signal intensity of each mRNA as computed by Affymetrix software that calculates the difference between the perfect match and mismatch oligonucleotides for each nucleotide sequence represented on the gene chip array). The mean difference values as described above reflect an expression signal well above "background" and suggest sufficient abundance of the expression products to provide a suitable marker. The second criterion was the preferential expression of the gene in the brain. In this case, we considered the gene to be preferentially expressed in the brain if its RNA expression value was 10-fold higher than spleen, kidney, skeletal muscle, lung, pancreas, heart, and small intestine. For the genes that met these 2 criteria, we then perused their human homologs in the bioinformatics databases Entrez Gene (http://ncbi.nlm.nih.gov/entrez/query.fcgi?dbϭgene), Online Mendelian Inheritance in Man (OMIM; http://ncbi. nlm.nih.gov/entrez/query.fcgi?dbϭOMIM), and Unigene (http://ncbi.nlm.nih.gov/entrez/query.fcgi?dbϭunigene).
preparation of antibodies
Nucleotide sequences encoding putative marker proteins were inserted into pGEX or pET vectors for production of protein in Escherichia coli. Proteins from pET vectors were purified with Qiagen Ni-NTA according to the manufacturer's protocol (The Qiaexpressionist 06/2003; Qiagen). Those from the pGEX vector were purified with immobilized glutathione from Pierce following the manufacturer's protocol. In some cases, plasmids were sent to GenWay Biotech, Inc., for large-scale production of protein from E. coli. These included pET 100 GAD67, pET 102 GAD67, pET 28 Zygin, and Zygin I. Quality control of the produced protein included analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, N-terminal Edman sequencing, and mass spectrometry as appropri-ate (31 ) . Protein concentration was estimated by absorbance at 280 nm with calculated extinction coefficients from the protein sequence plus construct obtained at the Swiss-Prot web site (http://www.expasy.org/sprot) and agreed with visual inspection of protein-stained bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Antipeptide immunogens were prepared as described by Li et al. (31 ) . Rabbits were immunized at Harlan Bioproducts for Science, Inc. Rabbit serum was immunopurified over an affinity column containing the cognate peptide or protein antigen.
Mice were immunized with 25 g protein/mouse immunogen in MPL-TDM adjuvant (Sigma-Aldrich) followed by at least 2 boosts in adjuvant and 1 boost in phosphate-buffered saline (150 nm NaCl, 50 nm sodium phosphate pH 7.2) 3 days before fusion. Armenian hamsters were immunized with 100 g protein/hamster in complete Freund's adjuvant followed by boosts in incomplete Freund's adjuvant and a final boost in phosphatebuffered saline. All fusions were performed at the Washington University School of Medicine Hybridoma Center. Monoclonal antibodies were purified from culture media on protein A-agarose or goat antimouse IgG-agarose or produced in ascites by Maine Biotechnology. All purified antibodies were dialyzed vs phosphate-buffered saline/ azide, pH 7.2, and protein concentration was estimated from absorbance at 280 nm with an absorptivity of 1.
. Subclass determination for monoclonal antibodies was performed with the IsoStrip reagent set from Roche. Minimum epitope assignment was based on immunostaining of ABIMED spot peptide arrays prepared at the MIT Biopolymers Facility. Each spot comprised a 10-mer contiguous peptide, and depending on the number of residues in the antigen of interest, either a 1-, 2-, or 3-residue offset was used to cover the entire antigen sequence. For example, for a 1-residue offset, spot 1 contains sequence 1-10, spot 2 contains sequence 2-11, spot 3 contains sequence 3-12, etc. Epitope mapping was attempted in some cases without success (noted as not established), and in others, it was not experimentally determined (noted as not determined).
Monoclonal antibodies were raised against visinin-like protein 1 (VLP-1) with a combination of DNA and protein injections. The vector VR1012 (Vical Inc.) and certain sequences from CTLA4Ig were used for the DNA injections. VR1012 has been optimized for protein production in mouse skeletal muscle, whereas sequences contained in CTLA4Ig were previously shown to greatly increase the antibody response in mice (32 ) .
Standard procedures used at the Hybridoma Center at Washington University in St. Louis for the creation and maintenance of the fusions were followed.
Antibodies against some of the candidate biomarkers, used to further characterize the utility of the protein products of candidate genes in the detection of brain injury, were purchased through commercial sources (Chemicon, Santa Cruz Biotechnology, Synaptic Systems, or Abnova Corp.).
western blot analysis
To confirm the presence of the proteins encoded by the candidate genes, we performed Western blots on unaffected human brain homogenate (Geno Technology, Inc.). Likewise, to assess the specificity of the coded protein for brain, we used a human tissue array (Geno Technology, Inc.; 50 g per tissue) and followed the manufacturer's specifications for the Western blot. The human tissue array included liver, brain, lung, kidney, spleen, testis, ovary, heart, pancreas, uterus, breast, cervix, rectum, prostate, thyroid, laryngopharynx, stomach, and skin. For some of the Western blots, different antibodies were mixed 1:1 before use so that more epitopes would be detected.
rat stroke model A rat stroke model was used to assess the appearance of VLP-1 in CSF as a function of time. Ischemia was induced in femoral vein-cannulated male Sprague-Dawley rats (Charles-River) by the previously described permanent (p) or transient (t) middle cerebral artery occlusion (MCAO) intraluminal filament method with some modifications (33 ) . Both pMCAO and tMCAO methods were used so that different degrees of injury could be obtained. As controls, some animals were subjected to sham operations (no filament placed). In brief, a midline incision was performed, and the right common, internal, and external carotid arteries were exposed. The external carotid and occipital arteries were ligated. The common carotid artery was ligated, and the internal carotid artery was temporarily closed. A small incision was made in the common carotid artery and a filament (3.0 Ethilon; heatblunted tip) was inserted into the internal carotid artery through the common carotid artery. The filament was advanced 17.5 mm to occlude the origin of the middle cerebral artery, either permanently or transiently (60 -90 min). The filament was secured in place in the right common carotid artery with a surgical nylon suture. After surgery, anesthesia (isoflurane) was discontinued, and the animals were allowed to recover.
CSF was collected by cisternal puncture when the animals were killed at either 2 h [sham (n ϭ 4), pMCAO (n ϭ 5), tMCAO (n ϭ 3)] or 24 h [sham (n ϭ 5), pMCAO (n ϭ 4), tMCAO (nϭ 3)] postsurgery. Groups were compared by an unpaired t-test (GraphPad Prism 4 software) at a significance of P ϭ 0.05. Blood (EDTA plasma) was collected, when possible, at 0, 2, 4, 8, and 24 h postsurgery (sham-and MCAO-operated).
quantitative assays
Sandwich immunoassays were developed for VLP-1 (monoclonal antibody 3A8 -1 as a capture antibody and rabbit antibody R3471 for detection), GAD67 (rabbit antibody Rb4043 as capture and Rb4610 for detection), and zygin (mouse monoclonal IG4. 4 
monoclonal 4G3.1 as detection) with ruthenium-labeled detection antibodies and electrochemiluminescent detection (Meso Scale Discovery). The lower limit of detection for the human plasma VLP-1 assay was set to be the first point on the calibration curve (0.04 g/L), which was at least 2 SDs above the background. In addition, 3 quality control samples were prepared by adding to heparinized plasma various amounts of postmortem CSF (high concentration of VLP-1), and were measured in every run. The interassay CVs for these samples were Յ15% (n ϭ 10).
Human heparinized plasma samples were retrospectively collected and frozen from excess clinical laboratory specimens that were obtained for routine care from a group of patients who presented to Barnes-Jewish Hospital with an acute neurological deficit between March and November of 2002. The medical histories of these patients were reviewed by one of us (J.-M.L.) without knowledge of the VLP-1 results, and patients with a discharge diagnosis of ischemic stroke and a clear time of onset of stroke were identified. Eighteen patients met this criterion, and their samples were analyzed.
Human heparinized samples were also obtained from healthy males and females and used as controls. These samples were not age-or sex-matched to the stroke patients.
Excess plasma samples from the Clincial Chemistry Laboratory were obtained with the approval of the Washington University IRB committee. Human CSF postmortem samples were obtained from Analytical Biological Services.
Results

identification of brain-specific genes
Twenty-nine genes were identified in the mouse as having reasonable abundance and specificity. Twenty-six of the 29 had human homologs that were confirmed to be enriched in the brain in humans by the abundance of expressed sequence tags derived from a brain source in Unigene. Two of the gene products, MBP and NSE, have been tested previously as brain injury markers and were excluded from further study. S-100B and GFAP, also previously looked at as brain injury biomarkers, did not meet the requirement of having a signal intensity Ͼ10 000 in the brain. They had signal intensities of 2500 and 5000, respectively. Of the 24 remaining human genes, 2 20 had a predicted protein sequence chain length of M r Ͻ70 000.
The M r 70 000 cutoff was selected because albumin, a protein abundant in the plasma, is known to enter the brain after injury because of damage to the blood-brain barrier (34 -36 ) , suggesting that this cutoff value for the egress of proteins from the brain might also be similar. The 20 genes and their gene products are listed in Table 1 in order of the mRNA production of their mouse homologs in brain.
Antibodies for the gene products of SLC32A1, VMP, and GABRG2 are not commercially available, nor had we generated antibodies as of the time of preparation of this report, and they could not be evaluated further. Thus, 17 possible brain-specific biomarkers were selected for further investigation. A summary of the antibodies used to further assess the candidate biomarker is shown in Table 2 (antibodies prepared internally) and Table 3 (antibodies purchased commercially). The immunogen was in the protein form unless otherwise indicated.
western blot analysis of gene products
Of the 17 gene products for which antibodies were available, Western blots showed strong signals from brain extracts for 13 of them. We did not find any signal for the gene products of the genes family member 1, proteolipid protein 1, neuronatin, or olfactomedin 1 (ZIC1, PLP1, NNAT, or OLFM1) with the antibodies described in Table 3 . We then tested the reactivity of the 13 gene products found in brain in different tissues by Western blot. The tissue Western blot for VLP-1 is shown in Fig. 1 . We scored the intensity of the Western blots of the tissue arrays for the 13 candidate gene products as follows: 5, very strong; 4, strong; 3, moderate; 2, weak; 1, very weak. Results are summarized in Table 4 . Western blots were also performed on human postmortem CSF at various dilutions, and the intensity of the bands compared visually with standards of the respective proteins. Zygin, neuroserpin, and GAD67 were below the limit of detection of this method (Ͻ2. rat stroke model VLP-1 was not detected in the CSF of sham-operated rats, whereas VLP-1 was found in high abundance in the CSF of MCAO-operated rats 24 h post injury (Fig. 2) , suggesting neuronal damage. The concentration [mean (SE)] of VLP-1 in the CSF of pMCAO rats was higher [16.8 (6. 
determination of vlp-1 in stroke patients
Thirty-nine plasma samples from unaffected donors were analyzed, and 37 of them were below the limit of detection of 0.04 g/L; the others had low values of 0.08 and 0.11 g/L. Of the 18 patients with confirmed stroke, only 2 had no samples with detectable VLP-1; most were considerably higher. Shown in Fig. 3 are the results at various times after stroke onset for 18 patients.
Discussion
Here, we describe the successful identification of brainspecific biomarkers with a systematic approach that in- volved the use of a mouse model and RNA expression analyses. We chose this approach as a sensitive way to identify proteins in brain that are not likely to be abundant in other tissues. We used this approach rather than a proteomic one because the mouse and human genome were known, means of rapidly obtaining tissue RNA and measuring the RNA expression were readily available, and interpretation of the data could be performed via bioinformatic analysis of public databases. We have compared this genomic approach with proteomic approaches in public databases for biomarkers of myocardial infarction and found the genomic approach superior (our unpublished data). The governing principle of our experiments was to search for markers of brain cell death, following the rationale that, upon death of the cells, their contents will enter into the extracellular matrix and further into the CSF. Because the blood-brain barrier is compromised during a stroke, we hypothesized that these biomarkers of brain cells injury will ultimately find their way into the systemic circulation. Through our analysis, we were able to identify genes that are preferentially and abundantly expressed in the mouse brain, and through the use of bioinformatics, were able to confirm the presence of the homologs of these genes in the human brain and gained further insight into their molecular characteristics. Western blot analyses showed expression in the brain with reasonable specificity for 10 of 13 of the gene products.
Furthermore, we developed sandwich immunoassays to detect the presence of some of these proteins in postmortem CSF and the CSF and sera of rats that had undergone stroke. Postmortem CSF was tested because it should reflect a condition in which the brain has been deprived of oxygen for a period of time long enough to cause extensive cell death. We put special emphasis on the development of a sensitive assay for VLP-1, given its ideal molecular characteristics (cytoplasmic protein of low molecular weight) and its high abundance in brain (most abundant mRNA in our search). Also, VLP-1, a calciumsensor protein found in mammalian CNS neurons, has been found to have a widespread distribution in the brain and to be abundant in all brain areas except the caudateputamen by in situ mRNA hybdridization studies (37 ) . We found similar intensity for Western blots of various human brain regions for VLP-1 (TB57 brain tissue region blot; Geno Technology) (data not shown).
We were able to demonstrate that VLP-1 was present in the CSF of an animal model of stroke and in the blood of stroke patients, as well as in CSF obtained postmortem. It was interesting that we were not able to detect VLP-1 in the serum of a rat model of stroke. This could be caused by several factors; we observed a decrease in the detection limit of our electrochemiluminescence assay with rat EDTA plasma compared with human heparinized plasma. Also, 24 h postinjury may not be long enough to allow VLP-1 to dissipate from the CSF into the bloodstream of the injured rats. These rats showed no increase in VLP-1 in CSF 2 h postinjury but did at 24 h. Similarly, 24 h may not be sufficient time for VLP-1 to appear in the blood. It would be interesting to have blood measurements in these animals beyond 24 h, but it will be difficult because there are complications in keeping these animals alive beyond 24 h postinjury. One study supports the idea of delayed appearance of neuronal injury biomarkers into the CSF, as has been reported for other biomarkers (38 ) . This study looked at CSF markers after acute stroke and saw no increase of total Tau in CSF at day 0 -1 after acute ischemic stroke, but we did see increase at days 2-3, peaking after 1 week and returning to unaffected levels after 3-5 months. Our studies of VLP-1 samples from patients after stroke are promising, but they were from samples obtained retrospectively from excess samples obtained for their routine clinical care and therefore were not systematic as regards time after stroke. Our results demonstrate that the identification of possible cell damage biomarkers via a genomic approach is a viable one and likely generally applicable for other cell damage markers. This approach has led to the identification of several potential biomarkers of brain injury. We are currently developing sensitive assays for these markers and further systematically assessing their ability to assess brain damage in human disease.
